IDEXX Laboratories (NASDAQ:IDXX) EVP Nimrata Hunt Sells 2,693 Shares of Stock

IDEXX Laboratories, Inc. (NASDAQ:IDXX) EVP Nimrata Hunt sold 2,693 shares of IDEXX Laboratories stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $661.54, for a total value of $1,781,527.22. Following the sale, the executive vice president directly owned 19,899 shares in the company, valued at approximately $13,163,984.46. This trade represents a 11.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

IDEXX Laboratories Stock Performance

IDEXX Laboratories stock traded down $3.98 during trading hours on Friday, hitting $656.73. The stock had a trading volume of 799,020 shares, compared to its average volume of 514,031. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $769.98. The company has a market cap of $52.29 billion, a PE ratio of 50.25, a price-to-earnings-growth ratio of 3.99 and a beta of 1.67. The company has a 50-day moving average of $673.82 and a two-hundred day moving average of $668.93. The company has a quick ratio of 0.90, a current ratio of 1.23 and a debt-to-equity ratio of 0.23.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Monday, February 2nd. The company reported $2.92 EPS for the quarter, missing analysts’ consensus estimates of $2.93 by ($0.01). The firm had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The business’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.53 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. On average, equities research analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently weighed in on IDXX shares. Leerink Partners set a $785.00 price objective on shares of IDEXX Laboratories in a report on Monday, November 3rd. Weiss Ratings cut IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, January 29th. BTIG Research cut their price objective on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a research report on Tuesday, February 3rd. Barclays reduced their price objective on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a research note on Thursday, February 5th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $830.00 target price on shares of IDEXX Laboratories in a research note on Tuesday, November 4th. Seven research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and an average target price of $783.33.

Hedge Funds Weigh In On IDEXX Laboratories

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. BDFS Capital LLC bought a new position in IDEXX Laboratories during the 4th quarter worth about $671,000. MidFirst Bank bought a new position in shares of IDEXX Laboratories during the fourth quarter worth about $2,960,000. Pacer Advisors Inc. raised its position in IDEXX Laboratories by 10.0% in the 4th quarter. Pacer Advisors Inc. now owns 13,965 shares of the company’s stock valued at $9,448,000 after buying an additional 1,269 shares during the last quarter. Titan Investment Management LLC bought a new stake in IDEXX Laboratories in the 4th quarter valued at approximately $1,675,000. Finally, Virtu Financial LLC acquired a new position in IDEXX Laboratories during the 4th quarter worth approximately $2,424,000. 87.84% of the stock is owned by institutional investors.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.